Windtree Therapeutics (NASDAQ:WINT) Shares Scheduled to Reverse Split on Monday, April 22nd

Shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) are set to reverse split on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 22nd.

Windtree Therapeutics Trading Down 15.3 %

Shares of WINT traded down $0.06 during trading hours on Thursday, hitting $0.34. The stock had a trading volume of 1,789,008 shares, compared to its average volume of 280,849. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.40 and a current ratio of 2.40. The firm has a market cap of $1.75 million, a P/E ratio of -0.04 and a beta of 0.61. The company’s fifty day simple moving average is $0.37 and its 200 day simple moving average is $0.67. Windtree Therapeutics has a 12-month low of $0.27 and a 12-month high of $7.79.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Windtree Therapeutics in a research report on Wednesday, January 3rd.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in Windtree Therapeutics by 54.1% in the second quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock valued at $151,000 after purchasing an additional 126,949 shares during the period. Envestnet Asset Management Inc. raised its position in Windtree Therapeutics by 97.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock valued at $36,000 after purchasing an additional 104,934 shares during the period. Millennium Management LLC increased its position in shares of Windtree Therapeutics by 411.1% during the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after acquiring an additional 64,232 shares during the last quarter. Vanguard Group Inc. purchased a new stake in shares of Windtree Therapeutics during the third quarter worth about $40,000. Finally, Virtu Financial LLC purchased a new stake in shares of Windtree Therapeutics during the fourth quarter worth about $28,000. 29.33% of the stock is owned by hedge funds and other institutional investors.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.